[Therapeutic application of myocardial cytoprotection].
Ribeiro
C
C
Catedrático de Cardiologia, Faculdade de Medicina de Lisboa.
D000083:Acetanilides; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002331:Carnitine / Q000627:therapeutic use; D006801:Humans; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D020108:Nicorandil; D010879:Piperazines / Q000627:therapeutic use; D000069458:Ranolazine; D014292:Trimetazidine / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000083:Acetanilides; D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D010879:Piperazines; D014665:Vasodilator Agents; D009536:Niacinamide; D020108:Nicorandil; D000069458:Ranolazine; D014292:Trimetazidine; D002331:Carnitine
A aplicação terapêutica da citoprotecção miocárdica.